Podcasts about Vertex

In this live client reading, I do a 90-Day Astrology Roadmap reading for Dino. He's anticipating a major shift in his job responsibilities and getting ready to move in with his girlfriend. He's also about to have transiting Uranus square his natal Sun and Venus, so I tell him how to make the best use of one of the most potent transits of his lifetime. Because it isn't just Uranus: Neptune and Pluto also aspect his Sun and Venus at the same time! RESOURCES New service: 90-Day Astrology Roadmap Reading Dino's 90-Day Astrology Roadmap report Dino's event list Dino's natal chart 2:56 - Quick natal chart overview 6:07 - 90-day report overview 7:24 - 90-day event list 8:09 - The Big Picture 11:32 - Relocation and relationship 12:07 - Key Timing Window 1, June 7-13 - Healing Relationship Patterns and Choosing Your Path 12:43 - Lunar nodes discussion 17:58 - T-Saturn conjunct Chiron and Eris in 7th house 21:35 -  Key Timing Window 2, June 14-25 - A Major Turning Point in Purpose, Identity, and Public Life 21:44 - Gemini New Moon aspecting the angles, Pluto, and Vertex 25:36 - Outer planet aspects to Mercury (Midheaven ruler) 27:45 -  Past career effects of outer planets aspecting Mercury 31:59 - Key Timing Window 3, June 26-July 10 - Reviewing Your Direction While Refining Your Message 35:02 - Key Timing Window 4, July 11-25 - Breaking Free From Old Identities and Embracing Authenticity 38:03 - T-Uranus square Sun and Venus 56:35 - All three outer planets aspecting Sun and Venus 1:02:16 - Highlighted Themes 1:07:17 - Most Favorable Windows 1:09:22 - Most Challenging Windows 1:11:29 - Bottom Line Summary Learn my invocations for healing and awakening in my FREE life-transforming video: Instant Divine Assistance: Your Free Guide to Fast and Easy Awakening, Healing, and More. Let my Awakening Plus membership help you awaken, heal, connect, and thrive! "This Week in Astrology" Free Session Entry. (2 chances each month to win a free session with me!) My forecasts in writing. My services: Astrology+, Energy Healing & Spiritual Guidance, life coaching, Deep Dive Trauma Healing, and more.  Apply to have me do a free reading for you on "This Week in Astrology." Support my work with your tax-deductible donation. Watch the video. May the stars light your way, Benjamin

What does good care actually look like for adults living with sickle cell disease?In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter focuses on navigating treatment options and disease modifiers. Dr. Kanter breaks down the most prominent medications and therapies available today, including hydroxyurea, crizanlizumab, L-glutamine, and blood transfusions, explaining how patients and providers can work together to personalize care and find the best treatment path.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the ⁠National Alliance of Sickle Cell Centers⁠ (NASCC).This episode is part of Sickle Cell 101's Care and Treatment 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Care and Treatment 101 sponsors: ⁠Vertex⁠, ⁠Chiesi⁠, ⁠Pfizer⁠, and ⁠Medunik⁠.

Chrisy and Dr. Kingzett, two women I met when we were all trying to raise our rare voices a little louder. Christine “Chrisy” Klavitter and Dr. Kristen Kingzett are both rare disease advocates, but more importantly, they are people living this reality every single day. Chrisy lives with Stiff Person Syndrome and Myositis. Kristen is an Internal Medicine physician and an ultra-rare cancer survivor. Together, we talk about what life with rare disease actually looks like—beyond the statistics. From delayed diagnoses (which can take years, even decades) to the emotional and physical toll of navigating a fragmented healthcare system, this conversation is honest, eye-opening, and necessary. More than 30 million people in the U.S. are living with a rare disease—defined as affecting fewer than 200,000 people. Yet despite those numbers, patients are still too often misunderstood, misdiagnosed, or left to navigate care on their own. Chrisy and Kristen share what an average day can look like, the full-time job of managing health (or caring for someone who is), and what happens when patients have to push back—even redirect—the so-called experts. We also dig into the bigger questions: Why does diagnosis still take so long—and how do we fix it? What do providers, institutions, and policymakers still not understand? What do you say to someone who believes “there's nothing I can do”? And where are we actually seeing progress in healthcare? What stands out most is this: patients are not passive participants in their care—they are often the ones holding it all together. About my guests: Dr. Kristen Kingzett is an Internal Medicine physician, educator, and advocate who brings both professional expertise and lived experience, including Juvenile Idiopathic Arthritis, Common Variable Immune Deficiency, and an ultra-rare cancer. She serves on Michigan's Rare Disease Advisory Council and Legislative Disability Caucus. Chrisy Klavitter is a healthcare policy and patient advocate, biologist, and recreation therapist. Living with Stiff Person Syndrome and Myositis, she works to bridge communication gaps between patients, providers, researchers, and policymakers to improve care for complex conditions. The takeaway? Rare disease may be defined by numbers, but its impact is anything but small. And if we build a healthcare system that works for rare disease patients, we build one that works better for everyone. Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

“Behind every breakthrough are countless failures no one ever sees—but that's exactly what makes progress possible.” Dr. Thomas Kaiser. When I have scientists on the podcast: they're some of the coolest, smartest, funniest people, and they're always willing (and excited) to explain what they do in ways you can actually understand. Dr. Tom Kaiser is no exception. He lives and works in Durham, North Carolina, and brings together an impressive mix of scientist, physician, and entrepreneur. His work focuses on designing better medicines using cutting-edge technology. He began his career at Emory University in Dennis Liotta's lab, working on antiviral drug discovery, and later helped pioneer early machine learning approaches in drug design. His research spans RSV, cancer, and neurodegenerative diseases, and he went on to earn his medical degree from the University of Oxford. Tom is now the co-founder and Chief Scientific Officer of Avicenna Biosciences, where he's leading the development of innovative therapies aimed at improving and saving lives. And my favorite detail from his bio? He ends it by mentioning the love of his life, his wife. I'll be honest, when I first met him, I told Dr. Kaiser he seemed like someone who must have been in a movie. He's just that cool. His Company: Dr. Thomas Kaiser shares the story behind his company's name, Ibn Sina, also known as Avicenna a true Renaissance figure of the Islamic Golden Age. A physician, philosopher, and scientist, Ibn Sina embodied the kind of multidisciplinary thinking that still drives innovation today. It's a powerful reminder that the roots of modern medicine, and the spirit of discovery stretch back centuries. The Part We Don't Talk About Enough Science is not a straight line. Not even close. Experiments fail. Clinical trials don't work. Hypotheses fall apart after years of effort. Funding can disappear. Progress can stall in ways that are frustrating and sometimes heartbreaking especially when patients are waiting. Dr. Kaiser speaks about this with a clarity and calm that really stayed with me. Because the truth is: scientists have to keep going anyway. They carry the weight of those disappointments and start again. They adjust, rethink, rebuild, and try again. Over and over. And that persistence? That's where breakthroughs come from. From the outside, it's easy to celebrate the wins ... the new drug, the successful trial, the headlines. But behind every one of those moments are countless failures no one ever sees. For families like ours, waiting, hoping, advocating it matters to understand that this difficult process is also what makes progress possible. Living the Dream What if you actually got to live the dream you had as a kid? In this conversation, Dr. Thomas Kaiser shares something surprisingly personal: he feels lucky to be doing exactly what he dreamed of as a child. That early curiosity grew into a career designing new medicines and pushing the boundaries of science. From imagination to impact, his journey is a reminder that sometimes those childhood passions really can shape the future. Go to Dr. Kaisers website:  https://www.avicenna-bio.com Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

What does good care actually look like for adults living with sickle cell disease? In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter breaks it down. She covers establishing a medical home, working with a sickle cell specialist, navigating the Emergency Department, and building an Individualized Care Plan that works for you.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the National Alliance of Sickle Cell Centers (NASCC).This episode is part of Sickle Cell 101's Care and Treatment 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Care and Treatment 101 sponsors: Vertex, Chiesi, Pfizer, and Medunik.

What does good care actually look like for adults living with sickle cell disease? In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter focuses on two pillars of quality sickle cell care: working with the right specialists and understanding the lab work that guides your treatment.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the National Alliance of Sickle Cell Centers (NASCC).This episode is part of Sickle Cell 101's Care and Treatment 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Care and Treatment 101 sponsors: Vertex, Chiesi, Pfizer, and Medunik.

Living Fully with CF: Christopher Cornejo's Journey from Diagnosis to Avatar This fast-moving and deeply engaging conversation features Christopher Cornejo, who brings a fresh and powerful voice to the cystic fibrosis community. Diagnosed with CF as an adult just three years ago, Christopher has quickly become an advocate, sharing his story on stage at a UCLA CF symposium and being honored by the Cystic Fibrosis Foundation as one of Southern California's Finest. What makes Christopher's story especially compelling is his perspective, shaped not only by his diagnosis, but by his career in film, including his work as a technical director on Avatar 2 and 3. In this heartfelt interview, Christopher opens up about his late diagnosis, navigating medical challenges, and how openness, community, and resilience have shaped his journey. We talk about his later diagnosis, balancing his health and his demanding film career, the importance of community and support along with his mental health and resilience.    Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

A mother, advocate and one woman's global fight for access. Beth Vanstone is working to ensure rare disease patients don't have to wait for the treatments they need to survive. Sometimes the most powerful friendships begin in the most unexpected places.  Beth Vanstone and I first connected on social media. At the time, we were simply two moms navigating the complicated, emotional, and relentless world of cystic fibrosis. But eventually the online messages turned into something more meaningful. Then, Beth attended one of The Bonnell Foundation's Gala events. That's when we finally met in person.  And from that moment on, we became dear friends.  It's proof that social media, when used for connection and purpose, can build incredible relationships. But what inspires me most about Beth isn't just our friendship. It's her relentless determination. Beth is the mother of Madi, who was diagnosed with cystic fibrosis at just eight months old. Suddenly Beth was navigating a healthcare system, researching treatments, learning medical language, and fighting for her daughter's future. Beth didn't stop there. Instead of focusing only on her own family, she chose to fight for every family. Today, Beth is a powerful advocate in Canada and a member of the Ontario Rare Action Group, where she works to improve access to life-saving therapies for people living with rare diseases like Cystic Fibrosis. And the reality she's fighting against is one many people don't understand. Most healthcare systems, not just in Canada but around the world were built to treat common diseases. They weren't designed for rare conditions that affect smaller populations. Because of that, patients with rare diseases often face enormous barriers: long approval timelines, delayed access to medications, and exhausting advocacy battles just to receive treatments that already exist. In some cases, patients wait months — even years — for medications that could dramatically improve or extend their lives. Beth is working to change that. Through her advocacy, she's pushing for reforms that could make a real difference for patients across Canada and beyond: • Faster access to innovative therapies • Improved newborn screening programs • Better diagnostic pathways • Centers of excellence for rare diseases • Removing financial barriers like deductibles that prevent families from accessing public programs And she's also raising an important global conversation. Here in the United States, lawmakers have debated policies like the Most Favored Nation Model, which look to international drug pricing systems like those in Canada and Europe as a model. But Beth reminds us that every system has challenges, and for rare disease patients, those challenges can be life-changing. Because when access to medication is delayed… Access is denied. And that's why advocacy across borders matters. She's not just advocating for her daughter. She's advocating for every patient still waiting for their breakthrough. And today, we're talking about what needs to change and how all of us can help make it happen. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Building software inside a frac and wireline giant is a different beast than doing it at a startup. Ben Dickinson and Raleigh Bumpers from NexTier Completion Solutions get into life under the Patterson UTI umbrella, the EOS platform, the Vertex automated pump control system, the shift from diesel to natural gas powered fleets, agentic AI in the field, and why the world genuinely stops if oil and gas stops. Plus Pittsburgh shale stories and a Colorado School of Mines reality check.Click here to watch a video of this episode.Join the conversation shaping the future of energy.Collide is the community where oil & gas professionals connect, share insights, and solve real-world problems together. No noise. No fluff. Just the discussions that move our industry forward.Apply today at collide.ioClick here to view the episode transcript. 0:00 The NexTier 60-second pitch2:00 Why integrating every service on location wins4:30 Ben's path from Pittsburgh to wireline to digital11:15 Raleigh's jump from computer science to the Eagle Ford17:00 If oil and gas stops, the world stops19:30 Pittsburgh, the shale boom, and incoming data centers21:30 Completions 10123:30 The EOS platform and Vertex automated pump control27:00 Earning trust from veteran hands on new software32:00 Generative AI versus agentic AI in the field34:00 Diesel, natural gas, and electric frac fleets41:30 Colorado School of Mines and the next generation44:00 The road to a fully autonomous well site46:30 The 80 percent AI failure rule debatehttps://twitter.com/collide_aihttps://www.tiktok.com/@collide.iohttps://www.facebook.com/collide.iohttps://www.instagram.com/collide.iohttps://www.youtube.com/@collide_iohttps://bsky.app/profile/collide-ai.bsky.socialhttps://www.linkedin.com/company/collideai

Bridging Two Countries, One Mission: Cesar and Nora Hernandez Fight for Spanish-Speaking CF Families “When Alex was diagnosed, we felt fear and responsibility. If we had access to information in Spanish, other families should too. No one should feel lost because of language.” Nora Hernandez From Mexico to Mission: How Cesar and Nora Hernandez Are Closing the CF Information Gap for Hispanic Families. “I came to this country to build a better future for my family. I never imagined that future would include fighting for awareness about cystic fibrosis, but now it's part of our mission.” Cesar Hernandez Cesar and Nora Hernandez were both born in Mexico, where accurate and accessible information about cystic fibrosis has not always been readily available. While progress is being made, with more experienced physicians and improving CF care, there is still significant work to do. In the United States, members of the Hispanic community are often underdiagnosed or diagnosed later than others. That gap in awareness and access is one of the reasons The Bonnell Foundation launched its CF Familia page, offering reliable information in both English and Spanish to help families navigate the complexities of cystic fibrosis. Cesar and Nora serve as ambassadors for this effort, creating videos that provide education, updates, and reassurance to Spanish-speaking families. Cesar also serves as a board member of The Bonnell Foundation, and we are deeply grateful for his leadership and heart for this community. Cesar originally came to the United States to build a better life and financially support his family in Mexico. After meeting Nora, he made the decision to stay and make the U.S. his permanent home. Together, they are raising two children, Scarlett and Alex, who was diagnosed with cystic fibrosis. Their story is one of resilience, faith, cultural pride, and advocacy. Transcript is also available on this podcast.     Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

On this week's episode, Josh Schimmer, Paul Matteis, Eric Schmidt, Yaron Werber, and special guest STAT's Allison DeAngelis open with what they describe as “a bananas week for biotech,” highlighting strong substantial secondary offerings, including Cytokinetics and Avalo Therapeutics. The conversation then turns to M&A, with multiple new deals announced in Q1 and continued activity this week, including UCB's acquisition of Candid Therapeutics for up to $2.2B, Angelini's $4.1B purchase of Catalyst Pharmaceuticals, and Bayer's acquisition of Perfuse for up to $2.45B. The group also reflects on what feels like the year of developmental-stage biotech, highlighting investor focus on companies with pipeline events such as Vertex and Biogen, while commercial-stage companies have lagged. In regulatory news, the co-hosts discuss Sanofi's decision to withdraw diabetes drug, teplizumab, from the Commissioner's National Priority Review program, broader concerns about shifting goalposts and political influence, and contradicting outcomes including Replimune's rejection versus Atara's reversal. On the data front, the hosts discuss Cytokinetics' Phase 3 results and subsequent $650M raise, as well as encouraging autoimmune data from Artiva Biotherapeutics. They also overview neurofilament as a biomarker following Clene's data, and J&J's decision to advance its DUET program despite failing to meet its primary endpoint in IBD. *This episode aired on May 8, 2026.

Finding Strength After Loss: A Conversation with Margarete Cassalina I first met Margarete Cassalina when we were hosted for dinner by Bob Emmelkamp at the North American Cystic Fibrosis Conference (NACFC). We connected immediately. There was an ease to our conversation, a shared understanding that doesn't require much explanation in the cystic fibrosis community. And I have to say, her husband Marc is just as wonderful. They are the kind of people you feel grateful to know. I'm so glad we are in this CF life together. Margarete is an author, speaker, and longtime advocate and fundraiser for the Cystic Fibrosis Foundation. But long before the stages, the fundraising events, and the national advocacy, she was a mom navigating the daily realities of cystic fibrosis. In 2006, her 13-year-old daughter, Jena, died from CF. In the depths of unimaginable grief, Margarete made a powerful decision: she would honor Jena's life not only with love, but with action. Since then, she has dedicated herself to storytelling, advocacy, fundraising, and speaking across the country about resilience, motherhood, loss, and the urgent need for continued research. Margarete's son, Eric, also lives with CF, and in this episode you'll hear more about how he's doing and what life looks like for their family today. This dynamic, incredible woman will inspire you. Her story is not only about loss it's about purpose. It's about choosing to move forward when standing still might feel easier. And it's about doing great things in the name of someone you love. To find her books go to Amazon.     Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Sponsored by Chargebee, subscription and revenue management → check out their startup offer: https://www.chargebee.com/startups Jeff Gibson, Founder of Kintsugi https://www.linkedin.com/in/jeffgibsonsf/?utm_source=chatgpt.com - Kintsugi, founded by Jeff Gibson, provides an AI-driven platform that automates global indirect tax compliance (VAT, GST, sales tax, etc.) for internet businesses, handling tax calculation, collection, and remittance. - The company targets SMBs and mid-market companies selling online, offering a simple, automated solution to a complex, high-risk compliance problem, resulting in high customer retention and low churn. - Kintsugi's founding insight came from the realization that businesses were paying more for tax compliance than for billing solutions, and that the market was underserved, especially for SMBs and mid-market companies. - The company raised a $2M pre-seed round in September 2023 from angels, followed by an $18M Series A led by Vertex.  - Jeff emphasizes the importance of founder conviction, qualifying investors for deep understanding of the problem, and building trust with customers in a “boring but essential” fintech space.

Education, connection, and community are at the heart  of our CF community. On Saturday, April 18th from 11:00 a.m. to 1:30 p.m. we gathered at the Next Step Gallery in Ferndale. Set in a bright gallery space surrounded by art, the event offered a welcoming environment for meaningful conversation, learning, and connection. It was pure joy with the smell of great food in the air. Food from my sister in laws restaurant, Bangkok Cuisine (in Royal Oak) filled the air, it smelled amazing and filled the air. Education Day is more than a traditional event. It's an opportunity for people living with cystic fibrosis, parents, caregivers, healthcare professionals, and advocates to gather in one space to share experiences and support one another. A highlight of the afternoon was our “live” podcast recording, offering attendees a chance to hear authentic conversations about life with cystic fibrosis, advocacy, and the challenges and hopes shaping the community today. We all talked about education, advocacy, and what lies ahead for the CF community. The relaxed setting allowed people to connect not just through information, but through shared experiences. Events like Education Day help strengthen the bonds within the CF community by reminding everyone that they are not alone in their journey. Whether you are living with CF, raising a child with the disease, working in healthcare, or supporting someone you love, this gathering is meant to inform, inspire, and bring people together. Every story matters. Every voice matters. And every person who attends becomes part of the conversation. To watch the the premiere of our Embracing Egypt podcast enjoy it here:  https://youtu.be/SlMscQ6Spjg   Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

In this episode, Paula introduces one of the most overlooked—and powerful—points in astrology: the Vertex. Often called the “point of fate,” the Vertex reveals what you're naturally aligned to attract in this lifetime, not what you have to chase. She breaks down where to find it in your chart, why the sign matters more than the house, and how it differs from the more conscious, action-driven Ascendant. Through real-life examples and personal stories, Paula explains how the Vertex shows up as unexpected opportunities, chance encounters, and life-altering moments that feel too perfectly timed to be random. From attracting relationships and resources to aligning with your life's path, this episode will help you recognize the patterns that have already been unfolding for you—and show you how awareness gives you leverage, not control. If you've ever felt like certain moments in your life were “meant to happen,” this episode will help you understand why.

“Being a CF aunt has shaped so much of my life. Now I get the opportunity to turn that love and connection into helping even more people at Breathe Strong CF."  Julie Dunn Eichenberg didn't just find the cystic fibrosis community, she's been part of it for more than 30 years as a proud CF aunt. That personal connection is what makes this next chapter so meaningful. Julie recently stepped into the role of Executive Director at BreatheStrong CF, where the focus is on helping people with cystic fibrosis live stronger, healthier lives through exercise, education, and empowerment. And while she brings decades of experience in leadership, fundraising, and relationship-building, she's honest about getting used to the role. She's learning. Listening. Figuring out the day-to-day. And really taking the time to understand how she can best serve the community in this new position. Before this, Julie spent 20 years at Turner Broadcasting System (now part of Warner Bros. Discovery), and later held leadership roles at Florida State University and Fan Data Insights. But no matter where her career took her, the CF community was always part of her life. She's also been deeply involved with the Cystic Fibrosis Foundation, serving as Chair of the Georgia Chapter and contributing at the national level. We talk about what it feels like to step into a leadership role that's so personal. The excitement, the pressure, and the responsibility that comes with it. Julie shares what she's learning, what's surprised her, and why her connection as a CF aunt continues to guide every decision she makes. Because for Julie, this isn't just a job,  it's personal. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Halozyme Therapeutics and Vertex Pharmaceuticals have entered a partnership to license Halozyme's Hypercon technology, involving a $15 million upfront payment and potential future milestones. Vertex will use the technology for up to three drug targets. Hypercon aims to reduce injection volumes, facilitating at-home drug administration. Halozyme will receive royalties on sales of products developed with Hypercon. This collaboration enhances Halozyme's drug delivery portfolio, which includes Enhanze technology, already licensed to major pharmaceutical companies.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

This Biotech CEO Created The RedTail Platform To Fight Cancer. Guest:Eric PomaCEO of Calidi Bio CLDI Company Name:Calidi BiotherapeuticsWebsite: https://www.calidibio.com/Ticker: NYSE: CLDIEric's Bio:Eric Poma, Ph.D. has served as Chief Executive Officer and board director of Calidi since April 2025 and brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of capital fundraising, big pharma collaboration agreements, and clinical program development.Prior to joining Calidi, Dr. Poma served as CEO of Molecular Templates (NASDAQ: MTEM), a clinical-stage biotech focused on the development of a novel class of therapeutic agents with unique biology in oncology. At Molecular Templates he raised over $250 million in equity financing and secured over $150 million in strategic capital through agreements with Takeda, Vertex and BMS. He previously served as Vice President, Business Development of Innovive Pharmaceuticals. Prior to that he held various senior level positions at Imclone Systems, Inc., primarily in business development. Earlier, Dr. Poma served as a Healthcare & Biotechnology Analyst with the healthcare fund Eagle Growth Investors, LLC.Dr. Poma received a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill, an M.B.A. from the Leonard N. Stern School of Business and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill.Company Bio:Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted genetic medicines for cancer and other diseases through its RedTail platform. The company's lead compound, CLD-401, is a systemically delivered oncolytic virus that expresses high levels of IL-15 superagonist only in the tumor microenvironment. The company expects to file an IND to initiate clinical studies for CLD-401 by the end of 2026. The company continues to advance what the RedTail platform can achieve and will be presenting additional data throughout the year.

Men with CF and Infertility: The Science, The Options, The Hope. Pete Proimos is an entrepreneur, a chronic illness advocate, and the founder of the Filotimo Foundation, a nonprofit dedicated to supporting individuals and families affected by cystic fibrosis. Diagnosed with CF as an infant, Pete kept his diagnosis private for decades. It wasn't until his forties that he chose to speak publicly about living with the disease, and that brave decision has changed lives. Pete is married to Annie, and together they are raising three children. His journey into fatherhood is part of what fuels his passion to make sure others with CF understand their options when it comes to building a family. Joining him in this important conversation is Colin Thomas, who leads the Family-Building Program at the Filotimo Foundation. Colin also lives with CF and became a father of five through IVF. In addition to his advocacy work, he serves as Vice President of Operations at IVY Fertility. He brings both professional expertise and deeply personal experience to this discussion, sharing honestly about the challenges and triumphs of becoming a parent with CF. One critical truth we discuss: Men with cystic fibrosis are not infertile because they don't produce sperm. Most are born without a connected vas deferens — the tube that carries sperm — which makes natural conception difficult. But with medical support, including sperm retrieval and IVF, biological fatherhood is often absolutely possible. This episode dives into the mission behind the Filotimo Foundation and the powerful work being done through its infertility and family-building program, work that is giving hope, clarity, and real options to families navigating CF. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Send us Fan MailWelcome to another episode of The Chasing Daylight Podcast! In this episode, Matt makes his triumphant return to the golf course at Mountain Falls following his knee surgery, putting the new joint to the ultimate test. We also dive deep into the latest professional tour news, including Gary Woodland's emotional victory in Houston and the fallout from Tiger Woods' recent DUI arrest. Plus, we talk LPGA history, dive into putting analysis software, and give our top course recommendations for a golf trip to St. George, Utah! Topics Discussed:Matt discusses playing 18 holes at Mountain Falls for the first time with his new knee. He shares that he had zero tentative swings and was driving the ball well. Jeremy gets dialed in on the practice green and range with a new Quantum Max driver and Denali shaft. We recap Gary Woodland's amazing win in Houston and praise his incredible stinger shots. We break down Tiger Woods pleading not guilty to his DUI and stepping away from professional golf. We also discuss the crazy aftermarket hype for his Sunday Red mugshot polo that sold out and is fetching top dollar on eBay. The crew highlights Hyo Joo Kim making LPGA history with multiple 61s. We also preview the upcoming full-field LPGA event at Shadow Creek. Matt shares his new venture into putting analysis using Vertex software. He explains how a session with putting coach Preston Combs inspired him to look deeper into putting metrics. A massive shoutout to Tim Flotte for providing incredible remote golf coaching. Matt details his great experience using the Skillest app to fix his swing basics. We give our top course recommendations for a trip to St. George. Suggestions include Copper Rock, Black Desert, Sand Hollow, and taking a short drive to Wolf Creek. Details on joining the Grassy App using Matt's referral code for a chance to win a Quantum driver. Special thanks to our show sponsor:

Explore how tax management is evolving through technology and strategic innovation to become a key driver of business efficiency and insight.=====Join Michael Bernard from Vertex as he unpacks the latest SAP Insider Benchmark Research on global tax management, revealing how tax departments navigate a rapidly changing landscape. From complex regulatory environments, such as fragmented e-invoicing standards in Europe, to critical pain points like automating tax control frameworks, this episode offers a rich exploration of what's top of mind for CFOs and CIOs. Learn how granular tax data is becoming a strategic asset for sales and marketing, the growing role of managed services amidst workforce shortages, and why the adoption of AI-driven tax automation is still in early stages despite its promising potential. Michael shares memorable stats, including the impact of retirements on CPA talent pools and strategies companies use to overcome compliance time constraints. Perfect for business leaders seeking practical insights on optimizing ERP environments for tax operations with future-ready technology. Listen, learn, and lead the transformation today.⁠⁠⁠⁠⁠⁠⁠Download Episode Transcript⁠⁠⁠⁠⁠⁠⁠Useful Links: ⁠⁠⁠⁠SAP Cloud ERP⁠⁠⁠⁠Follow Us on Social Media!SAP S/4HANA Cloud ERP: ⁠⁠⁠LinkedIn⁠⁠⁠=====Guest: Michael Bernard, Chief Tax Officer of Transaction Tax at VertexMichael Bernard is the Chief Tax Officer of Transaction Tax. In his role, he provides insight and thought leadership around tax department operations, U.S. indirect tax, tax risk management, and tax policy, as well as emerging tax trends. He is also responsible for influencing emerging technologies which meet the continuing regulatory changes of the corporate tax community. He is an executive-level tax attorney with a diverse portfolio of experience in corporate tax, administration, and finance, including a substantive knowledge of U.S. and international tax laws. Prior to joining Vertex, Michael was in various tax leadership roles at Microsoft Corporation for 28 years, the most recent being General Manager & U.S. Tax Counsel. He led teams in the following functional areas: direct and indirect tax controversy, sales and use, business license, property, tax IT, SOX, and telecommunications. He also co-led a corporate taxpayer advocacy group with the Washington Department of Revenue and was a Director on the Board of the Washington Research Council. He has also testified before administrative and lawmakers at both the federal and state level. Michael earned both a J.D. and a Bachelor of Science in Business Administration from Creighton University. He is a part-time lecturer of Law in the LLM program at the University of Washington School of Law. He also served on the board of directors, executive committee, and chaired committees for The Tax Executives Institute (TEI) for nearly 25 years.Host 1: Richard Howells, SAPRichard Howells has been working in the Supply Chain Management and Manufacturing space for over 30 years. He is responsible for driving the thought leadership and awareness of SAP's ERP, Finance, and Supply Chain solutions and is an active writer, podcaster, and thought leader on the topics of supply chain, Industry 4.0, digitization, and sustainability.Follow Richard Howell on ⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠ and ⁠⁠⁠⁠⁠⁠⁠X⁠⁠⁠⁠⁠⁠⁠=====Key Topics: Tax management, ERP, Tax control framework, Automation, Regulatory compliance, Managed services, Workforce skill gap, AI adoption, E-invoicing, Tax analytics

Three decades caring for patients with CF, that's Dr. Alan H. Cohen. His experience continues to shape everything he does today. As a pediatric pulmonologist (board-certified) , he has walked alongside patients through some of their hardest moments, including advanced lung disease and transplantation. Dr. Cohen was previously co-director of the largest pediatric lung transplant program in North America.Those years at the bedside are what ultimately led Dr. Cohen into drug development, where he has spent more than 25 years working to turn scientific innovation into real-world therapies for people who are still waiting for better options. As the Chief Medical Officer of Arcturus Therapeutics, he brings both clinical perspective and urgency to the company's work in mRNA-based therapies for cystic fibrosis and other rare diseases.“Clinical trials aren't just about science, they're about people who are willing to help move the field forward.”In this thoughtful and engaging conversation, Dr. Cohen reflects on how cystic fibrosis care has evolved over the past 35 years, from symptom management to breakthroughs in gene therapy and mRNA technology. Dr. Cohen discusses why clinical trials are essential to progress, especially for rare diseases, and why patient participation plays such a critical role in moving new therapies forward. Dr. Cohen also shares how the strength of the CF community continues to inspire his work, offering both realism and hope for the future of CF research.You'll also hear more about the personal side of this wonderful scientist! The Arcturus team packed Bonnell Foundation Hospital Bags with comfort products for caregivers, and CF adults for California CF Clinics. #teamworkClinical trials are an important step to understand whether a medicine works for its intended purpose.  Please see our active clinical trials below. For any questions email:  Community@ArcturusRx.com. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

On this week's episode, Grace Colón, Josh Schimmer, Eric Schmidt, and Brian Skorney open with a look at the macro backdrop. With market volatility and interest rate uncertainty, the hosts agree the macro is still “driving the bus,” tempering what might otherwise be stronger bullish sentiment. Even so, biotech continues to demonstrate relative resilience – XBI holding up better than the broader market – reinforcing the view that investors still want to own biotech. In deals, the co-hosts discuss Gilead's more than $2 billion purchase of Ouro Medicines for its autoimmune disease drug, Merck's $6.7 billion takeover of Terns to bolster its oncology pipeline, and Novartis' deal for Exellergy to strengthen its allergy portfolio. The conversation shifts to regulatory news, including the approval of Denali's Hunter syndrome drug, Avlayah, which comes shortly after the FDA rejected Regenxbio's gene therapy for the same condition. Other recent rare disease approvals are noted, with the group interpreting them as signs of slightly increased regulatory flexibility following leadership changes, though uncertainty remains across the health agencies.  The episode concludes with recent data news and market reactions from Sarepta and Arrowhead, Maze versus Vertex in kidney disease, Beam's data in AATD, Lyme disease vaccine data from Pfizer and Valneva, and a preview of data to be presented at AAD. *This episode aired on March 27, 2026. 

I've known Julie McCaffrey for years. She lives about 40 minutes from me, in Romeo, Michigan. Julie and her husband, Curtis, are raising four daughters, and their oldest, Jenna—now 20—lives with cystic fibrosis.What still makes me smile is how Julie and I were connected long before we ever met through the CF community… and we had no idea. We worked in the same building, in the same industry, at the same time. Both of us were in radio. I was a news reporter at WWJ, while Julie was a producer at WYCD. Even our podcast editor worked at another station in that very same building. Proof that sometimes the universe plants people in your orbit long before it tells you why.Julie's career path reflects both her curiosity and her compassion. She's worked in radiology, orthopedics, and labor and delivery. She's supported students as a paraprofessional in an elementary school and worked in a group home for adults with intellectual disabilities. Today, she works at Target—and genuinely loves it. Wherever she goes, she brings the same energy: presence, kindness, and care.At the heart of everything Julie does is a simple but powerful mission—to spread joy. She is deeply passionate about mental health advocacy, especially within the cystic fibrosis community. And despite the very real financial strain that comes with healthcare and insurance challenges, Julie continues to show up with an unwaveringly positive spirit. Not a performative positivity—but a grounded, generous kind that makes people feel seen.If you take just one thing from Julie today, let it be this:You are brilliant.You are beautiful.And you can do anything.(Suicide was discussed in this episode. Anyone needing help can call or text #988).  Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Halfway through the show STRIGGA had an unexpected and unfortunate situation where is X (formerly known as Twitter) account @STRIGGA was hacked. Therefore Dylan went solo for the last half or so after the 42 minute mark. We apologize for the inconvenience and will make it up one day!   On the return effort with Strig back from WxW we talk a bit about the state of the scene as well as an unexpected foray into the US and even Australian indies, but it leads us to Dylan's pick for a promotion to watch: Osaka Pro! We talked about the recent Tag Festival and the great storyline with VerteX and Rogue Nation, with great vibes of the promotion in particular. We then talk about the significance of Shinjuku FACE and how it will effect multiple companies going forward when it closes, along with the history of the building itself and Strig's past visits there.   After Dylan takes over solo he does a mini-run through of multiple big stories right now including:   - NJPW New Japan Cup - Stardom Cinderella Tournament - AJPW Champion Carnival Blocks - NOAH's 3.8 show featuring 2 great matches and a lot of rookies! - DG in Disarray and KAI vs. Kikuta being the next Dream Gate match   For more coverage of Japanese wrestling, and wrestling past and present please check out our Patreon for literally 1000s of hours of audio and written content as well, including the brand new EL Weekly Newsletter: https://www.patreon.com/easternlariat    Follow us on Twitter/X:     https://www.twitter.com/easternlariat    https://www.twitter.com/strigga       https://www.twitter.com/viva_zero   Follow us on BlueSky: @easternlariat.bsky.social @vivazero.bsky.social @strigga.bksy.social   Follow us on IG: https://www.instagram.com/easternlariat   If you would like more info check out Ruth (@ruthisanotter) and her great coverage of the company and it's Units, check her out on Twitter/X as well as their fantastic article on the subject: https://sixtyminutedraw.com/guide-to-osaka-pro-factions

“What if a blood draw didn't have to feel terrifying, Abby Rose is a child life specialist. And if you have never taken advantage of all they have to offer when your child is hospitalized, you're going to want to connect with them after you listen or watch this podcast!The North American Cystic Fibrosis Conference is one of those places you attend to learn—but it's also a place where you meet people who quietly leave a lasting mark. One of those people is Certified Child Life Specialist Abby Rose.Abby works at Seattle Children's Hospital, supporting both the Cystic Fibrosis program and Pediatric Hemodialysis. Originally from Wisconsin, she earned her bachelor's degree in Psychology and Family Studies from the University of Wisconsin–Eau Claire, followed by a master's degree in Child Life from Edgewood College.In her role, Abby focuses on outpatient care, working closely with children and families to create individualized coping plans. She supports kids through procedures many of us take for granted—blood draws, throat swabs, vaccinations, while also helping families navigate pill swallowing, treatment tolerance, sibling support, and the everyday challenges that can feel overwhelming in CF care.People like Abby made a profound difference for kids like one of my daughters—children who are frightened by procedures or don't fully understand what's about to happen to them. Child Life Specialists play a critical role in hospital settings, helping children feel safer, more informed, and more in control during some of their most vulnerable moments.Today, I'm excited to talk with Abby about the work she does—and why it matters so deeply.In our conversation, we'll explore:The Beads of Courage program and why it's so meaningful to children and familiesWhy Abby is such a strong advocate for transparency, open communication, and the rights of patients and familiesWhat draws her personally to Child Life work, and why she believes in it so deeplyAnd some of the “tricks of the trade”—the practical tools and techniques she uses to help kids feel calmer and more cooperative during procedures like blood drawsThis is a conversation about care, trust, and the people who help make hard moments just a little bit easier. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

On this week's episode, Sam Fazeli, Josh Schimmer, Paul Matteis, and Graig Suvannavejh kick off with a discussion on the impact of current geopolitics on biotech investor sentiment, noting that biotech is fundamentally insulated from oil prices and emphasizing that the sector is becoming cash‑flow positive at a pace not previously seen. Shifting to regulatory news, the group discusses Vinay Prasad's departure from the FDA and highlights that upcoming rare disease readouts will serve as a test of the FDA's flexibility. They also cover the FDA's new Adverse Event Monitoring System, which consolidates multiple adverse event reporting databases into a single platform. Next, the co-hosts highlight John Crowley's opinion piece in STAT News on Biotech's 50th anniversary (marked by the founding of Genentech), emphasizing the importance of protecting U.S. biotech and pharmaceutical pricing to sustain innovation. On the deal front, the group discusses Servier's $2.5B cash acquisition of Day One Biopharmaceuticals' oncology asset, as well as the recurring rumor of an Abivax takeover. The episode closes with a review of recent clinical data and company updates from IDEAYA Biosciences, Roche, Benitec Biopharma, RenovoRx, Vertex, Xenon, and Dianthus, along with broader commentary on FDA decision‑making following the approval of leucovorin. *This episode aired on March 13, 2025.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is undergoing substantial shifts, marked by leadership changes, regulatory updates, scientific breakthroughs, and strategic expansions.A significant development involves BioNTech's CEO Ugur Sahin and CMO Ozlem Tureci departing to establish a new company focused on next-generation mRNA technologies. This move has sparked discussions about BioNTech's future trajectory without its founders' guidance, considering their pivotal role in developing the COVID-19 vaccine. Analysts are concerned about BioNTech's ability to continue innovating and expanding its mRNA platform independently. As they transition roles, BioNTech is steering towards becoming a multiproduct commercial biotech entity, potentially diversifying its pipeline beyond vaccines towards broader therapeutic applications.In regulatory news, Novo Nordisk's U.S. headquarters recently received a warning letter from the FDA following an inspection, highlighting ongoing compliance challenges. This situation underscores the critical importance of maintaining rigorous quality standards in pharmaceutical manufacturing to avoid regulatory setbacks. Meanwhile, Novo Nordisk has partnered with Hims & Hers to distribute GLP-1 drugs Ozempic and Wegovy targeting diabetes management—a move resolving previous legal disputes while emphasizing digital health integrations into traditional pharmaceutical frameworks.On a more positive note, the FDA has approved leucovorin for an ultra-rare subset of cerebral folate deficiency without requiring clinical trials. This decision might suggest a shift towards more flexible regulatory pathways for rare diseases, potentially accelerating treatments for patients with unmet medical needs. The FDA is also working on its fourth revision of draft guidance on biosimilar testing requirements to streamline the approval process for these cost-effective alternatives to biologic drugs, thereby reducing barriers to market entry and fostering competition.In scientific advancements, Vertex Pharmaceuticals reported positive Phase 3 results for povetacicept, a kidney disease treatment poised for expedited FDA approval. This underscores ongoing innovation in addressing chronic conditions with high unmet needs. Vertex is advancing with a rolling biologics license application supported by late-stage data from the RAINIER study, aiming to address unmet medical needs within chronic kidney disease management.Meanwhile, researchers at Emory University are exploring artificial intelligence as a tool to detect heart disease through breast mammogram screenings, potentially revolutionizing cardiovascular risk assessment by integrating AI into routine diagnostics.CSL is investing $1.5 billion in a plasma-based medicine facility near Chicago, marking a strategic expansion aimed at enhancing production capacity for plasma-derived therapies. This move aligns with growing global demand for plasma products and underscores CSL's commitment to scaling operations to meet patient needs.Turning to other industry trends, Breakout Ventures has announced a $114 million fund dedicated to companies integrating artificial intelligence with scientific endeavors. This investment highlights the transformative potential of AI in accelerating drug discovery and optimizing research processes.Political scrutiny over the FDA's handling of rare disease drug approvals is intensifying. Senator Ron Johnson has launched an investigation into recent rejections, signaling potential future changes in how regulatory agencies balance innovation with safety and efficacy standards.The cell and gene therapy sectors are experiencing robust growth prospects. Recent analysis projects that this market will skyrocket to $146 billion by 2032, reflecting increasing investments and advSupport the show

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.What would life look like if Type 1 diabetes suddenly… stopped controlling every decision you make?In this episode of The Healthy Diabetic Podcast, Coach Ken sits down with Katie Beth Hand, a participant in the groundbreaking Eledon clinical trial, which is exploring a potential functional cure for Type 1 diabetes through islet cell transplantation and targeted immune therapy.Katie Beth shares her powerful story—from her unexpected diagnosis at age 26 to becoming Patient 9 in the Eledon trial, a study that has allowed several participants to live without insulin.Together, Ken and Katie explore the emotional reality of diagnosis, the challenges of navigating diabetes as an adult, and the excitement surrounding emerging research that may redefine the future of diabetes treatment.This conversation goes beyond the science. It highlights the lived experience of diabetes and the hope that real progress is finally being made toward a cure.

Diagnosed with cystic fibrosis at the age of fifty, Sheri Boyd brings a rare and powerful perspective to the CF community, one shaped by decades of undiagnosed illness, years of caregiving, deep resilience, and a strong foundation of faith. Sheri is a passionate advocate and, alongside her husband Shawn, co-founded S and S Rocks Life, a platform rooted in honesty, creativity, and hope.Sheri and Shawn share a uniquely intertwined journey. Shawn also lives with CF and is a double lung transplant recipient, and together they navigate post-transplant life with grit, transparency, and determination. They openly share both the challenges and the victories, offering a real and unfiltered look at what it means to live, and love, through cystic fibrosis.Through storytelling and advocacy, Sheri uplifts the CF community and supports CF-focused nonprofit organizations, drawing insight directly from lived experience. With a fascinating background in the music industry, Sheri also brings a distinctive lens to conversations about identity, judgment, and the courage it takes to show up authentically. Her story isn't about the absence of hardship, it's about perseverance, purpose, and choosing hope, even in the hardest moments. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

“Patients are waiting…”Those simple but profound words from Dr. Steve St. Onge set the tone for this conversation, and for why this work matters so deeply.Science has always fascinated me. I often joke that I'm not smart enough to be a scientist, but I have endless respect for the people who are, especially those who can take incredibly complex ideas and explain them in a way the rest of us can truly understand. This is why I know you're going to love my conversation with Dr. St. Onge. Steve is the Chief Business Officer at Clarametyx. Dr. St. Onge is a PharmD and MBA with more than 15 years of experience spanning clinical care, medical affairs, and leadership in biotechnology. What stands out most about Steve isn't just his impressive résumé, it's his ability to clearly explain the science, the strategy, and, most importantly, the urgency behind the work Clarametyx is doing.I first met Steve in person at the North American Cystic Fibrosis Conference (NACFC) in Seattle, where we had the opportunity to really connect and talk about Clarametyx's approach. Their work focuses on targeting biofilm-driven inflammation and progressive lung damage, an area of significant unmet need for people living with chronic respiratory diseases, including cystic fibrosis. In this conversation, Steve breaks down what biofilms are, why they're so difficult to treat, and how Clarametyx is thinking differently about tackling the inflammation and lung damage they cause.We also talk about the long road of drug development, the responsibility that comes with working in rare disease, and why the phrase “patients are waiting” isn't just a saying, it's a call to action. This episode is an honest, accessible, and hopeful look at science in motion, and at the people behind the research who are driven by the patients counting on progress.If you've ever wanted a clearer understanding of how innovative science moves from idea to impact—and why time matters so much, his is a conversation you won't want to miss. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

"Ever moment, every day is worth celebrating." Somer LoveSomer Love has spent her life choosing hope, dreaming big, and showing up fully for each day. Diagnosed with cystic fibrosis at just 11 months old, Somer has grown into a powerful and compassionate advocate for the CF community.Guided by her belief that “Every moment, every day is worth celebrating,” Somer brings joy and purpose into everything she does. She often reminds others that “laughter is key,” a mindset that has helped carry her, and those around her, through the challenges of life with cystic fibrosis.Through her work, Somer is dedicated to raising awareness, educating others, and offering hope, especially to families navigating a new CF diagnosis. In 2001, she founded Love to Breathe®, a platform created to educate, spread awareness about cystic fibrosis, and share love and connection around the world.Big on birthdays, Somer's parents made celebration part of her story in an unforgettable way. Every year, they placed Somer's photo on a billboard. What began as a birthday tradition became something much bigger, raising awareness about cystic fibrosis in a way that stops people in their tracks. What that billboard did for awareness will give you chills. It's something you will never forget. You'll have to listen to the podcast to hear the story!Somer knows that fighting CF isn't something anyone can do alone. Her journey is deeply rooted in the strength of her support system and the community that stands beside her. She continues to advocate not only for her own future, but for a cure, for everyone living with cystic fibrosis.Somer sums up the reason to advocate. This quote is on her website: "The goal isn't to live forever, but to create something that will"-Chuck Palahniuk Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

When Insurance Gets Between Doctors and PatientsDr. Elizabeth Ames and Dr. Caleb Bupp are deeply committed to their patients. But like so many clinicians today, they're spending an extraordinary amount of time battling insurance companies instead of practicing medicine.Between prior authorizations, step therapy requirements, and outright coverage denials, physicians and their teams are buried in paperwork, often at the direct expense of patient care. Time that should be spent listening, diagnosing, and treating is instead consumed by forms, phone calls, and appeals.Boston Globe reporter Jonathan Saltzman raised the concern and Dr. Ames brought it to my attention. The reporter talks about, a new program rolled out by Blue Cross Blue Shield of Massachusetts. The insurer says the initiative is designed to control rising healthcare costs for its 3 million members, noting that costs have increased by 30 percent since 2021. But, the program specifically targets physicians who bill for the most expensive visits. The reason for the increased expense, which is discussed in our podcast, is because doctors are choosing to spend more time with rare disease patients who have complicated health issues. They need to spend more time with complex medical needs patients than say, someone with a sore throat.Drs. Ames and Bupp warn that this approach fundamentally misunderstands patient care, particularly for those with complex or rare conditions. “These patients don't need less time; they need more” says Dr. Ames. Physicians argue that policies like this risk rushed appointments, strained doctor/patient relationships, and poorer outcomes. Nowhere is this more concerning than in the rare disease community, where delays and denials can be devastating.Dr. Elizabeth Ames and Dr. Caleb Bupp talk about what this looks like in real life. As pediatric geneticists, they see firsthand how insurance barriers impact families already navigating diagnostic odysseys, uncertainty, and fear. Their work sits at the intersection of cutting-edge science and deeply human stories, and insurance interference often disrupts both. Dr. Ames, “Usually we get faxes saying, this has been denied and we start working on it. But the family gets a letter that the drug they need, the process is delayed by a “no”. We try and have good communication and say, “hey, we got this denial,” we're working on it. But I think it's deaths by a thousand cuts for the family. Families take the denial as, “I'm not worth of coverage, and that's really hard”. Dr. Bupp says they have had to hire genetic counselors, a job that didn't exist even 5 years ago, “We have a job description in our organization for it now because of the complexities that come with trying to unravel these insurance situations”.We should also note that Dr. Ames, Dr. Bupp, and I all serve on the Rare Disease Advisory Council (RDAC) in Michigan. “I think rare disease advocacy, there is power in numbers. One person can be a huge difference maker, but it's not one plus one equals two. It really exponentially grows, and I think with things like rare disease advisory councils, that gives you a better connection within your state, for state government and for advocacy. And I also think, or I hope, that it gives a place for an individual to plug in and that can then magnify and amplify. their voice so that they're not alone”. Many states have RDAC's, You can see if your state has an RDAC. For more on the Michigan RDACIn this article and in the podcast we are not speaking on behalf of the council, but it's important to understand why bodies like RDAC exist in the first place. Michigan is home to approximately one million people living with rare diseases, and the RDAC was created to ensure their voices, and experiences help shape policy. RDAC meetings are open to the public, and anyone in Michigan can participate and offer public comment. We hope you join our meetings via zoom (sometimes hybrid).This conversation isn't just about insurance policies. It's about time, trust, and whether our healthcare system truly serves patients, especially those with the most complex needs. Speak up, share your story. Advocate. Make a difference, Mold the future, for future generations.To look at the Everylife Diagnosis Odyssey https://everylifefoundation.org/delayed-diagnosis-study/ discussed in the podcast.  Everylife impact of diagnosis: https://everylifefoundation.org/burden-study/ Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Innovating Medicine: How Science, Collaboration, and Curiosity Transform Patient CareIt is always inspiring to speak with true innovators on this podcast, the people who don't just follow the science, but actively push it forward, turning ideas into real-world solutions that change lives. We are honored to welcome Dr. Jeffry Weers whose work has profoundly impacted the cystic fibrosis (CF) community and beyond.Dr. Weers is a distinguished pharmaceutical scientist with more than 35 years of experience designing and developing novel drug-delivery systems. Throughout his career, he has focused on innovative treatments for CF, working across formulations, biologics, small molecules, and combination products. His achievements include an extensive patent portfolio and a remarkable publication record, but what truly sets him apart is his ability to translate ideas into treatments that improve patient lives.  I found that many scientists like Dr. Weers are soft spoken. They don't want to brag about their scientific successes, they just want their work to speak for itself.  Dr. Weers is so darn smart!  He won't toot his own horn, so I must!  He's a great person who is filled with so much hope for the future.One of Dr. Weers' most notable contributions is the invention of the Tobi Podhaler, a device that transformed how inhaled antibiotics reach the lungs. For people living with CF, this innovation has meant more effective, easier-to-administer treatment, significantly improving daily quality of life. His work exemplifies the power of scientific innovation to directly impact patient care.Dr. Weers delves into both the breakthroughs and the challenges of drug development. He shares insights into the ongoing hurdles of developing inhaled medications, including inhaled insulin, and emphasizes the regulatory obstacles that can slow the introduction of new anti-infectives. Yet, he remains optimistic about the future, highlighting the role of collaboration among scientists and the potential of AI to enhance medical imaging, diagnosis, and patient outcomes.Dr. Weers also stresses the critical importance of addressing infectious diseases in CF patients and the responsibility of the scientific community to advocate for better treatments. Beyond his professional achievements, he reflects on the personal side of being a lifelong scientist, sharing how interests like farming provide balance and perspective in a demanding career.I particularly loved recording this episode because Dr. Weers has a rare ability to make complex science accessible, explaining the “why” behind innovations in a way anyone can understand. For anyone curious about the intersection of science, medicine, and human impact, this conversation is both enlightening and inspiring.To watch a fabulous video that explains the creation of what it takes to get medicine into the lungs, view here: You Tube link: https://www.youtube.com/watch?v=fwglM8Zo4m0Inhaled drug delivery in CF/ YouTube link: nother YouTube link: https://youtu.be/iV27VdieQbo Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Daelyn James, is someone who understands the power of owning your story. Diagnosed with cystic fibrosis at just four years old, she remembers what it felt like to go from a carefree childhood to one filled with treatments, doctor visits, and a reality she wasn't ready to face. For a long time, Daelyn kept her CF hidden because she was worried it would change how people saw her or limit what she could do.But in high school, everything shifted. Daelyn made the brave decision to stop running from her diagnosis and start embracing it as part of who she is. And that choice changed her life.Now 25, she proudly lives with CF and uses her experiences to raise awareness, connect with others, and offer hope. Her message is simple but powerful: even in the hardest moments, there is strength, there is goodness, and there is always a way forward.I'm so excited for you to hear her story.To connect with Daelyn visit her on IG: https://www.instagram.com/daelyn_j/To connect with Somer Love her IG is Love to Breath: https://www.instagram.com/lovetobreathe/ Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

We're joined by droqen (The End of Gameplay, Starseed Pilgrim), Darius Kazemi (Tiny Subversions, Harvard Applied Social Media Lab), and Tara Macalister (mathematician, composer) to discuss Vertex Dispenser, the second game in our year-long exploration of the work of Michael Brough. Next Month: Kompendium Audio edited by Dylan Shumway. Discussed in this episode: Vertex Dispenser https://store.steampowered.com/app/102400/Vertex_Dispenser/ Michael Brough's Website https://www.smestorp.com/ Four color theorem https://en.wikipedia.org/wiki/Four_color_theorem Graph coloring https://en.wikipedia.org/wiki/Graph_coloring  Starcraft II https://starcraft2.blizzard.com/en-us/ Splatoon https://splatoon.nintendo.com/  Dota 2 https://www.dota2.com/home  Droqen's rare color graph/explanation https://discord.com/channels/690388280767807518/1442554518092120186/1465039921147412510  lots of michael brough games https://smestorp.itch.io/lots-of-michael-brough-games  The Sense of Connectedness https://forums.tigsource.com/index.php?topic=16151.0  Kompendium https://mightyvision.blogspot.com/2012/06/kompendium.html The End of Gameplay https://droqen.itch.io/the-end-of-gameplay Utopia Clicker https://tinysubversions.com/game/utopia/ A Jackpot of Skulls https://brainfruit.studio/games/jackpot _update() Jam https://adamatomic.itch.io/update-jam   https://secretlives.games/  https://discord.gg/tslog https://www.patreon.com/tslog https://www.youtube.com/eggplantshow

Rainforest enables vertical software companies to embed payment processing directly into their platforms - solving the complexity that previously forced software companies to direct customers to separate banks or resellers for payment processing. Founded by Joshua Silver, who spent nearly 20 years in payments starting with PatientCo (a healthcare billing company that scaled to process billions for major healthcare organizations), Rainforest now serves as the enabling layer for thousands of vertical software companies. In this episode of BUILDERS, Joshua shares the unconventional GTM decisions that shaped Rainforest's trajectory: from making contracts a product feature to implementing a zero bugs policy, and why he measures podcast success by qualified lead conversion rather than download counts. Topics Discussed: The embedded payments opportunity: why software companies stopped directing customers to banks Building in highly regulated environments where traditional MVP approaches fail The extended foundation-building phase required before processing the first payment Transitioning from 2.5-3 years of founder-led sales to a scalable GTM motion Using contract terms as competitive differentiation rather than negotiation leverage Implementing a zero bugs policy and its impact on service costs and retention Building thought leadership through the Payment Strategy Show and Vertex conference Lead quality metrics over vanity metrics for content investments GTM Lessons For B2B Founders: Hire from the industry and invest disproportionately in technical onboarding: Rainforest maintains one of the highest concentrations of payments talent on a percentage basis—nearly everyone has worked in payments or payments-adjacent roles. But hiring isn't enough. Joshua obsesses over training because in complex sales, prospects ask detailed technical questions and "the moment that you give bad answers or don't know your stuff, they're going to detect that and that's going to detract a lot from the trust." When selling technical infrastructure, surface-level product knowledge kills deals. Every touchpoint—engineers, support, account execs—must understand not just how the product works, but why it works that way. Engineer your standard contract to eliminate negotiation cycles: Joshua inverted conventional wisdom by making Rainforest's standard contract "overly favorable to the client"—no hidden terms, no punitive clauses, no exclusivity provisions. The result: "We don't have to spend a lot of legal time going back and forth. We don't have to invest a lot of time and by the way, burning a lot of goodwill too in contract negotiations." Prospects consistently report the legal process was shockingly easy compared to competitors. This isn't about being naive—it's strategic capital allocation. Joshua's philosophy: "Pick the fights that really matter and everything else is just rounding." Time spent in legal negotiations is wasted time that could be spent onboarding customers. Embed sales capabilities into your customer success function: Rainforest trains their CS team on negotiation tactics, value selling, and objection handling—competencies rarely developed in post-sale teams. Joshua noted the primary goal is customer assistance, but growth is an underlying objective. This isn't about making CS "do sales"—it's about equipping them to have commercial conversations when customers naturally express expansion interest. The key enabler: strong product-market fit means "we don't have to sell it that much. It's really a conversation about solutioning." Enforce a zero bugs backlog in high-stakes environments: Joshua's unofficial core value—"don't f with the money"—manifests in their zero bugs policy. It's not that they never create bugs; it's that "we don't tolerate living with them. We don't have a backlog of bugs to fix." When a bug is validated, they fix it immediately. His head of engineering recently discussed this on a podcast because people find it radical. The payoff: "When you have a higher quality product, you don't have to invest as much in service because the product just works and you have naturally happy customers." For infrastructure products where errors cascade into customer incidents, the accumulated cost of technical debt vastly exceeds the upfront investment in quality. Qualify content success by whether it's converting your ICP: Joshua rejects vanity metrics entirely. When asked about podcast ROI, he said: "I'd rather have 100 highly qualified listeners that are great targets for us than have 100,000 listeners and not have 100 qualified ones." They track this rigorously—every inbound lead is asked how they discovered Rainforest, and an increasing percentage cite the podcast. Prospects explicitly say "we heard the podcast and nobody else is putting this content out there." The metric isn't downloads; it's whether qualified buyers are self-identifying through your content and entering sales conversations pre-educated and pre-sold. Build ecosystem assets without demanding immediate attribution: Rainforest launched Vertex—a curated conference for vertical software founders and operators—that explicitly isn't a Rainforest sales event or user conference. Joshua doesn't track lead conversion from the conference: "That's not one of the key metrics. We actually look at NPS score as one of the key metrics. Did people find value in the conference?" They're running it twice this year because attendees report it's the highest-quality conference they attend annually. His philosophy: "Go create value, legitimate, genuine value for the ecosystem and they will come to us." They deliberately limit attendance to several hundred and choose venues that physically can't accommodate massive scale—maintaining intimacy as a forcing function against growth-for-growth's-sake. Plan for extended pre-market build phases in regulated industries: Joshua's advice for payments founders: "Make sure you know what you're getting into. It's a big build and there's very low tolerance for misses." Before processing their first payment, Rainforest had to achieve PCI compliance, SOC2 compliance, and implement comprehensive security infrastructure. Only then could they begin customer development with close network contacts. He contrasts this with his standard founder advice: build an MVP, sell quickly, get feedback, iterate. In payments, that playbook doesn't work—"you actually have to build so much of the foundation first just to process your very first payment." Founders in regulated spaces need patient capital and realistic timelines that acknowledge compliance infrastructure isn't optional. Institutionalize "ruthlessly simplify" as an operating principle: One of Rainforest's core values is ruthless simplification, which Joshua applies to "the legal contract, the engineering documentation, anything." He asks his team repeatedly when reviewing anything: "Can we simplify it? Can we simplify it? Can we simplify it?" The output quality dramatically improves. He references the Tim Ferriss framing: "What would this look like if it were simple?" When applied consistently, it cuts approximately 50% from plans, strategies, and deliverables—even when the creator thought they were already building simply. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

About Rasmus Holst:Rasmus Holst is the CEO of Zensai (formerly LMS365), where he built a learning management business from $0–30M ARR, bootstrapped, completed three acquisitions, and pioneered the “Human Success” category as a replacement for Human Resources. He has been part of management teams delivering exits just shy of $1bn, raised +$50m for companies like Wire and Huddle, and worked across PE-backed (Carlyle, Warburg Pincus) and VC-funded (General Atlantic, Index, Vertex, Morpheus, Iconical) environments.His experience spans scaling start-ups from zero revenue, operating +$300M Lines of Business at Syniverse, and leading branding and B2B storytelling efforts, including Zensai's Red Dot Award and Great Place to Work recognition. Rasmus has managed global teams across 14 countries, traveled to +100 nations, and lived in Denmark, Luxembourg, and San Francisco, making him a leader with a uniquely international view on culture, growth, and balance. In this episode, Dean Newlund and Rasmus Holst discuss:Turning HR into Human Success and redefining what organizations measureLinking performance, learning, and engagement into one real-time scoreFeedback rituals and kudos culture as engines of team identityMeasuring soft skills through sentiment and peer behaviorAI as a teammate that amplifies human contribution instead of replacing it Key Takeaways:Replace annual HR lag metrics with weekly human success check-ins tied to learning, performance, and engagement.Institutionalize positive feedback (e.g., weekly kudos) to normalize critique, build confidence, and surface soft-skill leaders.Track soft skills through peer sentiment and recognition patterns rather than relying solely on manager evaluations.Use generationally agnostic baselines (showing up as a good human and delivering success) to align multicultural/global teams. "There's a high correlation between people who get a lot of kudos and those who are really good at a lot of soft skills.” — Rasmus Holst Connect with Rasmus Holst:  Website: https://zensai.com/LinkedIn: https://www.linkedin.com/in/rasmusholst/    See Dean's TedTalk “Why Business Needs Intuition” here: https://www.youtube.com/watch?v=EEq9IYvgV7I Connect with Dean:YouTube: https://www.youtube.com/channel/UCgqRK8GC8jBIFYPmECUCMkwWebsite: https://www.mfileadership.com/The Mission Statement E-Newsletter: https://www.mfileadership.com/blog/LinkedIn: https://www.linkedin.com/in/deannewlund/X (Twitter): https://twitter.com/deannewlundFacebook: https://www.facebook.com/MissionFacilitators/Email: dean.newlund@mfileadership.comPhone: 1-800-926-7370 Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it.

Running for Time: Chad Eddy's Mission Against Cystic FibrosisFor Chad Eddy, the fight against cystic fibrosis isn't abstract, it's personal. He's the proud uncle of two nieces born with CF. One is still living.When his goddaughter was born in 1998, (he asked their names not be used) the second of his nieces diagnosed with cystic fibrosis, Chad's world changed. He quickly realized that simply walking in charity events or asking friends and family to donate wasn't enough. Love demanded action. Hope demanded movement.He wanted to do more. He wanted to be part of the generation that finds the cure. It's his motto.In 2017, Chad's heart broke when one of his nieces lost her courageous fight with CF. But even in grief, he found his purpose. He made a promise to her, and to his living niece, and to every person living with CF, that he would keep running toward a cure.Now, Chad isn't running for a medal. He's running for time. Time for those who can't breathe freely. Time for families waiting on a cure. Time for the breakthroughs that can change everything.His mission has taken shape in an extraordinary endurance challenge: running 6.5 miles every 6.5 hours for 65 straight hours , all to raise $65,000 for cystic fibrosis research.This is not a race. It's a test of heart, exhaustion, and purpose, run one step, one story, one promise at a time.Already, more than 80 donors have stepped forward, contributing over $11,000 to support Chad's mission. But this is no longer just a personal challenge, t's a movement.Through a short documentary film, that movement, and its heartbeat, will be captured forever.For everyone still fighting for breath, Chad runs because every moment counts. And he won't stop until cystic fibrosis is a disease of the past.For more information and to donate:: https://fundraise.cff.org/roseup2025/65milesin65hoursforCF To see the trailer for Generation: Cure: https://youtu.be/YyI_rNXuNAI?si=pk_tBY3NZkdtdfTn Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

When Jennifer joined New Hope in 2018, she didn't just take a job — she stepped into a calling. What began as a role coordinating outreach and events quickly became a mission to change how communities understand and support grief. With her compassion, creativity, and drive, Jennifer helped New Hope grow from a local resource into a lifeline for families across the region. Her leadership was soon undeniable — first as Interim Executive Director, then officially taking the helm in January 2020 — guiding New Hope through seasons of transformation, expansion, and profound impact.Under Jennifer's direction, New Hope has launched new loss-specific grief groups, expanded programming, and reached grievers in more communities than ever before. She continues to build on her expertise through national training with the National Alliance for Children's Grief and other organizations, ensuring that every program New Hope offers is trauma-informed, compassionate, and deeply effective.Jennifer's community involvement runs wide and deep — she serves on multiple local health and wellness councils, partners with school districts, and facilitates leadership and family development programs, includingThe Leader in MeandThe 7 Habits of Highly Successful Families. She's also been invited to speak and moderate at events like Hegira Health'sFocus on Zerosuicide prevention conference, sharing insights on resilience and healing.Today, Jennifer not only leads New Hope but helps train other organizations on how to support those in grief. She's currently helping design age-specific grief curriculum for students — empowering young people to understand loss, express emotion, and find hope. She's seen the full circle of healing firsthand: those once supported by New Hope returning to offer that same compassion to others, creating a community where no one grieves alone. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Join Jay Gunkelman, QEEGD (the man who has analyzed over 500,000 brain scans), Dr. Mari Swingle, author of i-Minds, and host Pete Jansons for another engaging NeuroNoodle Neurofeedback Podcast episode discussing neuroscience, psychology, mental health, and brain training.✅ Topic 1 Explained: Sleep's Hidden PowerWhy no one markets “8 hours of sleep” in January despite it being the easiest, most powerful mental-health booster — orexin drive, anterior cingulate rumination, and why fatigue gets misclassified as just physiological.✅ Topic 2 Deep Dive: Neurofeedback Fatigue RisksOver-training protocols leads to "gym fatigue" in the brain. Jay & Mari explain balancing excitation/inhibition, avoiding hyper-stability, and how master clinicians accelerate results.✅ Topic 3 Insights: Stimulation PrimersPhotobiomodulation, HRV syncing, harmonics, cranial sacral — 10 minutes pre-session boosts neuroplasticity for better outcomes.✅ Additional Topics:

At the 2025 Medical Innovation Olympics, a powerful all-star expert panel moderated by Melissa Norcross (Vice President, Corporate Strategy, Hyland Software) featuring Eddie Power (CEO, Empower Medical, former Global Medical Affairs Leader at Pfizer), Vivek Mukhatyar (Senior Director, Medical AI Team Lead, Pfizer), and Ravi Kiran Koppichetti (Senior Analyst, Manufacturing Technology, Vertex; former Lead IT Data Engineer, Novo Nordisk) cut through the hype and delivered a practical playbook for leaders in healthcare: 1) Fall in love with the problem, not the tool; 2) Think in systems, not silos; and 3) Train your people, not just your models.Timeline00:00 Highlight 1: Why AI Innovation Fails When the Problem Is Mis-framed01:20 Highlight 2: Probable vs Precise Decisions: Where AI Helps vs Where Governance Must Lead03:38 Highlight 3: Falling in Love with the Problem, Not the Solution04:38 Highlight 4: Non-Patient AI Use Cases: Process, Partnership & Proof06:00 Leadership in the Age of AI: Framing the Right Questions08:52 Systems Thinking in Healthcare Innovation (Hepatitis C Case Study)11:35 Constraints in Medical Affairs: Where Humans Must Stay in the Loop13:19 AI as “Intelligence on Tap” vs Clinical Decision Authority17:53 Defining Target Conditions and What “Done” Really Means20:15 Systems Failures in Real-World Healthcare Environments22:50 How Providers, Payers, and Pharma Are Using AI Today25:47 Who Decides: Human vs AI Agents in Regulated Healthcare27:18 Industry 4.0 Explained: Integrating OT and IT in Pharma Manufacturing30:33 Data Quality, Trust, and Why Most Organizational Data Is Unstructured32:03 Probabilistic AI vs Precision Decisions: A Leadership Framework34:35 Trust, Evaluations, and Human-in-the-Loop AI Design39:11 Why 95% of AI Pilots Fail — and the Role of AI Ambassadors43:08 Closing Reflections: Systems Thinking, Learning Loops, and Fearless Curiosity

A black leather jacket, black hoop earrings, black T-shirt and pants. You may visualize a rock star, and Colin Hemez is a rock star of sorts, but he actually works in a white coat, a doctors coat. Yes, he's a scientist.Dr. Hemez brings a remarkable blend of science, creativity, and purpose to the fight against cystic fibrosis. Colin was born in France and raised in the high-desert town of Los Alamos, New Mexico, an environment steeped in scientific discovery. Summers interning at Los Alamos National Laboratory sparked his early fascination with how innovation can change lives.At Yale, he explored the intersection of engineering and art, studying biomedical engineering alongside art history to understand both the precision of science and the elegance of design. But it was a research trip to the Arctic University of Norway that set his path in motion. While building mathematical models of antibiotic resistance, a challenge many people with cystic fibrosis face, Colin discovered his true calling.Today, he's a PhD student in Dr. David R. Liu's renowned laboratory at Harvard, working at the cutting edge of gene editing for cystic fibrosis. Every day, Colin is pushing boundaries, imagining a future where science doesn't just treat CF but has the power to rewrite its story.We had to so much fun talking in this podcast. Born in France we talk about Colin's wonderful siblings and parents. They're all incredibly smart and making a huge difference in our world.Outside the lab, Colin reflected on the grounding role of art, music, and outdoor exploration, coping mechanisms that keep him connected to the world he's trying to impact. Looking ahead, he's both hopeful and driven: gene editing for cystic fibrosis is no longer a distant dream but a rapidly approaching reality with global implications. His aspirations are bold, but so is the science.In his view, the future of CF research depends on collaboration, imagination, and staying rooted in why the work matters: to bring healthier, longer lives within reach for every person living with this disease. We sure love his passion for science. You won't want to miss this Amazing Podcast. To watch Colin's PhD  https://drive.google.com/file/d/1HizIGiqGdKDgIifT7HF9t0UDVgv0tOKE/view Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Centenas de pessoas na TIM fazem data analytics fora da área de tecnologia. Advogados criando modelos no Vertex. Profissionais de marketing usando DataProc. Como equilibrar autonomia com governança sem criar Shadow IT? No décimo sétimo episódio do Hipsters.Talks, PAULO SILVEIRA, CVO do Grupo Alun, conversa com JONE VAZ, Diretor de Data e IA da TIM, sobre cultura de dados, citizen developers, IA Academy e como democratizar tecnologia em uma empresa de 60 milhões de clientes. Uma conversa sobre o futuro da TI corporativa. Prepare-se para um episódio cheio de conhecimento e inspiração!

Mentorship can accelerate a career or quietly stall it depending on how intentional you are. Too often leaders collect mentors without clarity, structure, or purpose. In this episode, Scott and Scott break down what effective mentorship really looks like and how emerging leaders can use it as a strategic advantage. They unpack the three types of mentors every leader needs at different seasons, explain why your boss is rarely the right choice, and show how to bring structure to the relationship from day one. This conversation turns mentorship from a vague idea into a practical growth tool that builds confidence, perspective, and momentum.  In this episode we talk about and answer these questions:  • why mentorship matters beyond advice and encouragement  • how to choose the right mentor for the leader you want to become  • whether your direct supervisor should be your mentor  • the difference between a sponsor, a coach, and a guide  • how to set SMART goals for your first 90 days as a mentee  • what responsibilities the mentee must own for the relationship to work  Click Here to Submit Your Questions  Links from show:  Explore ServiStar's Vertex leadership training  Learn more about ServiStar's Emerging Leaders program Subscribe to ServiStar Leadership Podcast on your favorite streaming service   

Vertex head of corporate development Nigel Rughani discusses dealmaking, sourcing and integration strategy on the buy side.

Send us a textIn this episode, Matt sits down with "Putting Guru" Preston Combs, owner of Preston's Putting, for a deep dive into the art and science of rolling the rock. Whether you are a gear junkie obsessed with the latest Zero Torque putters or a player struggling to read greens, this conversation covers it all. Preston debunks the myths about AimPoint, explains how to properly test a putter before buying it, and takes Matt through a live lesson that transforms his setup.In This Episode, We Cover:The Truth About AimPoint: Preston explains why AimPoint is suitable for beginners and high-handicappers, not just pros. He also debunks the myth that AimPoint slows the game, noting that a proper read should take only about 10 to 12 seconds.Green Books vs. Feel: While Green Books are great for approach shots, Preston explains why relying on them solely for putting can be tricky due to angle variationsThe "Zero Torque" Debate: Do you actually need a Zero Torque putter? Preston reveals that while they help some, they can hurt players who rely on torque for feel in transition.How to Buy a Putter: Don't just grab what's popular. Preston shares a drill that uses a quarter or a dime to test start lines in the store before you drop hundreds of dollars.Blade vs. Mallet: Why "cavity back" putters might be hiding your mistakes and why some pros are sticking to blades for better feedback.The "Base Stroke" System: Understanding how to regulate stroke size and tempo so you stop guessing how hard to hit the ballMatt's Lesson: Preston diagnoses Matt's "long follow-through" as a symptom of a short backswing and fixes his setup by adjusting his forward bend to improve structural stability.Resources Mentioned:Preston's Putting: https://www.prestonsputting.com/AimPoint: https://aimpointgolf.com/ Vertex Sensor: https://vertex-golf.com/Quotes from the Show:"If you can't control the face on a three-mile-an-hour club head speed swing, it's not the putter." - Matt "I'm a proponent of any tool that allows players to better understand what's getting ready to happen to their golf ball." - Preston Combs "It looks like you're trying to hit that eight iron 160 yards." - Preston on forcing a putting stroke. Support the showSpecial thank goes out to our show sponsors:

Happy Witchy Wednesday! I'm so excited to unpack the magic of the Vertex and Anti-Vertex with you. They're not talked about enough imo. These two hidden points in your chart reveal where fate meets you and where you become the fated person in someone else's life. We go through the signs, the houses, synchronicity windows, and how to find yours. Honestly, mine has helped me make sense of my own path and purpose. A soft and mystical look at meaningful encounters and the people who shift your path.NEW SUBSTACKraquellemantra.substack.comRAQUELLE + YOMyourownmagic.comig @raquellemantrafb group your own magicFIND YOUR VERTEX + ANTI-VERTEXastro-seek.comSPONSORS' SPECIAL OFFERS hereOur Sponsors:* Check out Everyday Dose and use my code MAGIC for a great deal: https://everydaydose.com* Check out Happy Mammoth and use my code MAGIC for a great deal: https://happymammoth.com* Check out Kensington Publishing: https://www.kensingtonbooks.comSupport this podcast at — https://redcircle.com/your-own-magic/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy